These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prospects for reform of the IND/NDA processes: Part I. Romansky MA J Clin Psychopharmacol; 1982 Oct; 2(5):358-61. PubMed ID: 6752215 [No Abstract] [Full Text] [Related]
6. The clinical value of FDA class C drugs approved from 1981 to 1988. Yasuda SU; Woosley RL Clin Pharmacol Ther; 1992 Dec; 52(6):577-82. PubMed ID: 1458766 [No Abstract] [Full Text] [Related]
7. Are drugs within a class interchangeable? Furberg CD; Herrington DM; Psaty BM Lancet; 1999 Oct; 354(9185):1202-4. PubMed ID: 10513728 [No Abstract] [Full Text] [Related]
8. Overview of drug discovery and development. Ator MA; Mallamo JP; Williams M Curr Protoc Pharmacol; 2006 Dec; Chapter 9():Unit9.9. PubMed ID: 22294181 [TBL] [Abstract][Full Text] [Related]
9. Current trends in IND-NDA procedures. Brilhart KB Bull Parenter Drug Assoc; 1971; 25(3):132-9. PubMed ID: 5093249 [No Abstract] [Full Text] [Related]
10. Microdosing Studies in Children: A US Regulatory Perspective. Roth-Cline M; Nelson RM Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312 [TBL] [Abstract][Full Text] [Related]
11. Pharmaceuticals in the environment. Sherer JT Am J Health Syst Pharm; 2006 Jan; 63(2):174-8. PubMed ID: 16390933 [No Abstract] [Full Text] [Related]
12. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Eichelbaum M Clin Pharmacokinet; 1982; 7(1):1-22. PubMed ID: 7042170 [No Abstract] [Full Text] [Related]
13. Present attitudes of governmental drug regulatory agencies. Noel PR Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283 [No Abstract] [Full Text] [Related]
14. FDA mulls changes to bioequivalence standards. Traynor K Am J Health Syst Pharm; 2010 Jun; 67(11):864. PubMed ID: 20484205 [No Abstract] [Full Text] [Related]
15. Drug safety: experimental programs. Zbinden G Science; 1969 May; 164(3880):643-7. PubMed ID: 4888107 [No Abstract] [Full Text] [Related]
16. FDA moves closer to new requirements for NTI drugs. Traynor K Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797 [No Abstract] [Full Text] [Related]
17. The utility of pharmacokinetics to the pharmaceutical industry. Nelson RL J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):565-9. PubMed ID: 977797 [TBL] [Abstract][Full Text] [Related]
18. CONTROL OF DRUG TOXICITY IN THE UNITED STATES OF AMERICA. WESTON JK; WESTON K Practitioner; 1965 Jan; 194():16-21. PubMed ID: 14259685 [No Abstract] [Full Text] [Related]
19. The IND application. Ferkany JW; Williams M Curr Protoc Pharmacol; 2008 Sep; Chapter 9():Unit 9.10. PubMed ID: 22294234 [TBL] [Abstract][Full Text] [Related]